Radiopharmaceutical firm Cell>Point is planning to launch a phase II clinical study to evaluate the effectiveness of its technetium-based imaging technology for use in the heart.
The study will evaluate the use of the company's 99mTc-EC-DG (technetium-99m-ethylenedicysteine-deoxyglucose) agent in diagnosing the presence of viable tissue in regions of the myocardium damaged by myocardial infarction or chronic coronary artery disease. The Centennial, CO, company has already completed a phase I safety study, as well as canine heart remodeling studies.
Originally developed for oncology applications, Cell>Point believes the radiopharmaceutical could improve diagnostic accuracy in assessing whether a patient would benefit from coronary revascularization. Cell>Point plans to study the effectiveness of 99mTc-EC-DG in other cardiac indications, including a study in conjunction with myocardial perfusion imaging in women (who often exhibit false-positive results following the perfusion stress procedure), and a study of early diagnosis of congestive heart failure onset.
By AuntMinnie.com staff writers
June 2, 2006
Related Reading
Biotech firm Cell>Point sees promise for oncology SPECT, May 20, 2005
Copyright © 2006 AuntMinnie.com
